Drug – bio-affecting and body treating compositions – Cystic fibrosis
Reexamination Certificate
2002-04-15
2008-10-07
Richter, Johann (Department: 1616)
Drug, bio-affecting and body treating compositions
Cystic fibrosis
C424S557000, C424S681000, C435S199000
Reexamination Certificate
active
07432308
ABSTRACT:
The equilibrium between G actin and F actin is shifted towards the F actin confirmation with compounds such as the ionic form of magnesium or potassium. The higher amount of F actin decreases the inhibition of nucleases such as DNAse I by monomeric G actin. The increased performance of the nuclease results in better treatment of patients suffering from cystic fibrosis or other diseases with viscous mucus.
REFERENCES:
patent: 5464817 (1995-11-01), Stossel et al.
patent: 5985339 (1999-11-01), Kamarei
patent: 0406732 (1991-01-01), None
patent: 0998945 (2000-05-01), None
patent: WO 91/16909 (1991-11-01), None
patent: WO 92/09290 (1992-06-01), None
patent: WO 94/03189 (1994-02-01), None
patent: WO 94/22465 (1994-10-01), None
patent: WO 96/01627 (1996-01-01), None
patent: WO 96/11016 (1996-04-01), None
patent: WO 98/37096 (1998-08-01), None
patent: WO 00/03746 (2000-01-01), None
Medline Plus Medical Encyclopedia: Asthma Oct. 27, 2004.
Medline Plus Medical Encyclopedia: Lung disease Oct. 30, 2004.
Medline Plus Medical Encyclopedia: Systemic lupus erythematosus Jul. 12, 2004.
Shak et al. Proc. Natl. Acad. Sci. USA 1990, 87, 9188-9192.
Campbell et al. The Journal of Biological Chemistry 1980, 255(8), 3726-3735.
Pan et al. Biochemistry 1997, 36, 6624-6632.
Prince et al. Clin. Exp. Immunol. 1998, 113, 289-296.
Davis, et al. Lupus 1999, 8, 68-76.
MedlinePlus Medical Encyclopedia: Cystic Fibrosis Jun. 8, 2005.
MedlinePlus Medical Encyclopedia: Lung diseases Oct. 30, 2004.
MedlinePlus Medical Encyclopedia: Mesothelioma Oct. 31, 2005.
Dibbern DA. Wiskott-Aldrich Syndrome Jun. 10, 2005.
MedlinePlus Medical Encyclopedia: Systemic lupus erythematosus Jul. 12, 2004.
Akman et al. Autoimmune manifestations of the Wiskott-Aldrich Syndrome. Seminars in Arthritis and Rheumatism 1988, 27(4), 218-225.
Shak et al. Aerosolized recombinant DNase I for the treatment of cystic fibrosis 1995, 107, 65-70.
Shak et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum Proc. Nat. Acad. Sci. USA 1990, 87, 9188-9192.
Campbell et al. The effect of divalent cations on the mode of action of DNase I. J. Biol. Chem. 1980, 225(8), 3726-3735.
MedlinePlus Medical Encyclopedia: Asthma Oct. 27, 2004.
Maruyama, “Effects of KC1, MgC12, and CaC12 Concentrations on the Monomer-Polymer Equilibrium of Actin in the PRescence and Absence of Cytochalasin D1”, J. Biochemistry, vol. 96, No. 3, pp. 605-611, 1984.
Levy et al., “Bioactivity of Gentamicin in Purulent Sputum from Patients with Cystic Fibrosis or Bronchiectasis: Comparison with Activity in Serum,”The Journal of Infectious Diseases148(6): 1069-1076 (1983).
De Smedt Stefaan
Demeester Joseph
Sanders Niek
Arnold Ernst
Clark & Elbing LLP
Richter Johann
Universiteit Gent
LandOfFree
Therapeutic compositions for the treatment of a respiratory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compositions for the treatment of a respiratory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compositions for the treatment of a respiratory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3993877